Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?

Executive Summary

The prospects for approval of Bristol-Myers Squibb/AstraZeneca's saxagliptin by its user fee goal date of April 30 seem remote at best
Advertisement

Related Content

Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential
Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential
Liraglutide’s Future Uncertain: Panel Voices Concern Over Cancer And CV Risk
Groundhog Day For Byetta, GLP-1 Class: Is Regulatory Winter Nearly Over?
Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns
Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia – FDA Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS050920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel